We verified that HDAC2 is amplified in CRC, its expression is negatively correlated with NLRP3, and combined analysis of HDAC2 and NLRP3 can be used as an indicator to predict patient survival. This evidence concerns the gene NLRP3 and colorectal carcinoma.